Table 3

Funding given to support the research and development of the ChAdOx technology and the Oxford–AstraZeneca vaccine based on freedom of information to University of Oxford, sorted by funder type

Funder typeChAdOx technology (to SG and AH only), £ (%)Oxford–AstraZeneca vaccine, £ (%)Total, £ (%)
 UK government5 511 316 (8.0)33 354 469 (95.5)38 865 785 (37.3)
 Overseas government26 252 085 (37.9)0 (0.0)26 252 085 (25.2)
 Charity21 468 904 (31.0)1 217 835 (3.5)22 686 739 (21.8)
 PPP12 943 763 (18.7)272 286 (0.8)13 216 049 (12.7)
 Research institution0 (0.0)68 106 (0.2)68 106 (0.1)
 Industry1 970 370 (2.8)0 (0.0)1 970 370 (1.9)
 Other1 166 941 (1.7)0 (0.0)1 166 941 (1.1)
 Total69 313 38034 912 696104 226 076
  • An approximation of the total amount of funding received for the adenovirus vector technology and the Oxford–AstraZeneca vaccine, for each funder type, is given in the total column.

  • AH, Professor Adrian Hill; ChAdOx, chimpanzee adenovirus-vectored vaccine; PPP, public–private partnership; SG, Professor Sarah Gilbert; UK, United Kingdom.